An MRI before a prostate biopsy finds more dangerous cancers, fewer harmless ones

For a man with a raised PSA who has never had a prostate biopsy, doing an MRI scan first — and taking tissue only from areas the scan flags — finds more of the cancers that matter and fewer of the ones that do not, compared with the older approach of sampling the gland blindly [s1]. In the PRECISION trial, MRI-targeted biopsy diagnosed clinically significant cancer in 38% of men against 26% with standard ultrasound-guided biopsy, while 28% of men in the MRI group avoided a biopsy entirely because their scan was clear [s1].

A different question from "should I be screened"

Whether to screen for prostate cancer with a PSA test at all is a genuinely contested trade-off, driven by overdiagnosis, and it is covered separately. This is the next question down the line: once a man's PSA is elevated and cancer is suspected, how should doctors look for it? For decades the answer was a transrectal ultrasound-guided (TRUS) biopsy — 10 to 12 needle cores taken semi-blindly across the gland, a procedure that can cause bleeding, pain and infection [s1][s2]. Multiparametric MRI changes the pathway by showing where suspicious tissue actually is, so that some men can skip the biopsy and others can have it aimed.

What PRECISION found

PRECISION randomised 500 men with suspected prostate cancer and no previous biopsy to one of two pathways: an MRI, with a targeted biopsy only if the scan looked suspicious, or a standard TRUS biopsy [s1]. Of the 252 men assigned to the MRI arm, 71 (28%) had scans that were not suggestive of cancer and so had no biopsy at all [s1].

Among all men in each arm, clinically significant cancer was found in 95 of 252 (38%) with the MRI pathway versus 64 of 248 (26%) with standard biopsy — an adjusted difference of 12 percentage points (95% CI, 4 to 20; P=0.005) [s1]. Just as important, the MRI pathway found fewer of the clinically insignificant cancers that lead to overtreatment: an adjusted difference of −13 percentage points (95% CI, −19 to −7; P<0.001) [s1]. The trial met its threshold for non-inferiority and, on the confidence interval, showed the MRI strategy was actually superior [s1].

The accuracy behind the pathway

The earlier PROMIS study established why the pathway works, by testing MRI against a far more thorough reference standard [s2]. Of 740 men enrolled, 576 underwent MRI followed by both a standard TRUS biopsy and a template mapping biopsy — a dense grid of samples that serves as a stand-in for ground truth [s2]. On that reference test, 408 of 576 men (71%) had cancer, and 230 (40%) had clinically significant cancer [s2].

For detecting significant cancer, MRI was far more sensitive than TRUS biopsy — 93% (95% CI, 88–96) versus 48% (42–55) — meaning the blind biopsy missed roughly half of the important cancers the scan caught [s2]. The authors estimated that using MRI to triage men could let about 27% avoid a primary biopsy and, when biopsies were then aimed by the scan, could detect up to 18% more significant cancers than biopsying everyone the old way [s2].

The limits, stated plainly

MRI is a triage test, not a verdict. Its weakness is specificity: in PROMIS, MRI was correct in ruling cancer out only 41% of the time (95% CI, 36–46), against 96% for TRUS biopsy [s2] — so a suspicious scan is often a false alarm, and a clear scan does not guarantee there is no cancer. Scan quality and reader experience vary between centres, which the trials, run at expert sites, do not fully capture. And the procedure carries risk regardless of pathway: in PROMIS, 44 of 740 men (5.9%) had a serious adverse event, including 8 cases of sepsis [s2].

What it means

MRI-first has since become the recommended pathway in major guidelines, and PRECISION and PROMIS are why: aiming the needle finds more of the cancers that can kill and fewer of the ones best left alone, which is the same balance that governs monitoring low-risk disease rather than rushing to treat it [s1][s2]. The scan does not remove the hard judgement — a positive MRI still needs a biopsy to confirm, and pathology itself is now being re-examined with AI tools — but it moves the whole process toward finding the right cancers in the right men.

Sources

• [s1] New England Journal of Medicine — MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis (PRECISION) (2018-03-19)
• [s2] The Lancet — Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS) (2017-01-19)